ES2190466T3 - Gen brca2 de susceptibilidad al cancer de mama ligado al cromosoma 13. - Google Patents

Gen brca2 de susceptibilidad al cancer de mama ligado al cromosoma 13.

Info

Publication number
ES2190466T3
ES2190466T3 ES96309211T ES96309211T ES2190466T3 ES 2190466 T3 ES2190466 T3 ES 2190466T3 ES 96309211 T ES96309211 T ES 96309211T ES 96309211 T ES96309211 T ES 96309211T ES 2190466 T3 ES2190466 T3 ES 2190466T3
Authority
ES
Spain
Prior art keywords
cancer
human
brca2
gene
invention refers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96309211T
Other languages
English (en)
Other versions
ES2190466T5 (es
Inventor
Sean V Tavtigian
Alexander Kamb
Jacques Simard
Fergus Couch
Johanna M Rommens
Barbara L Weber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endorecherche Inc
HSC Research and Development LP
Myriad Genetics Inc
University of Pennsylvania Penn
Original Assignee
Endorecherche Inc
HSC Research and Development LP
Myriad Genetics Inc
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27504907&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2190466(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Endorecherche Inc, HSC Research and Development LP, Myriad Genetics Inc, University of Pennsylvania Penn filed Critical Endorecherche Inc
Publication of ES2190466T3 publication Critical patent/ES2190466T3/es
Application granted granted Critical
Publication of ES2190466T5 publication Critical patent/ES2190466T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE GENERALMENTE AL CAMPO DE LA GENETICA HUMANA. ESPECIFICAMENTE, LA PRESENTE INVENCION SE REFIERE A METODOS Y MATERIALES UTILIZADOS PARA AISLAR Y DETECTAR UN GEN DE PREDISPOSICION AL CANCER DE MAMA HUMANO (BRCA2), ALGUNOS ALELOS MUTANTES QUE CAUSAN SUSCEPTIBILIDAD AL CANCER, EN CONCRETO CANCER DE MAMA. EN CONCRETO, LA INVENCION SE REFIERE A MUTACIONES DE LINEA GERMINAL EN EL GEN BRCA2 Y A SU USO EN EL DIAGNOSTICO DE PREDISPOSICION AL CANCER DE MAMA. LA PRESENTE INVENCION SE REFIERE ADEMAS A MUTACIONES SOMATICAS EN EL GEN BRCA2 EN CANCER DE MAMA HUMANO Y A SU USO EN EL DIAGNOSTICO Y PROGNOSIS DE CANCER DE MAMA HUMANO. ADICIONALMENTE, LA INVENCION SE REFIERE A MUTACIONES SOMATICAS EN EL GEN BRCA2 EN OTROS CANCERES HUMANOS Y A SU USO EN EL DIAGNOSTICO Y PROGNOSIS DE CANCERES HUMANOS. LA INVENCION TAMBIEN SE REFIERE A LA TERAPIA DE CANCERES HUMANOS QUE TIENEN UNA MUTACION EN EL GEN BRCA2, INCLUYENDO TERAPIA GENICA, TERAPIA DE SUSTITUCION DE PROTEINA Y MIMETICA DE PROTEINA. LA INVENCION SE REFIERE ADEMAS A LA INVESTIGACION DE FARMACOS PARA TERAPIA DE CANCER. FINALMENTE, LA INVENCION SE REFIERE A LA INVESTIGACION DE LAS MUTACIONES DEL GEN BRCA2, LO CUAL ES UTIL PARA DIAGNOSTICAR LA PREDISPOSICION AL CANCER DE MAMA.
ES96309211T 1995-12-18 1996-12-17 Gen brca2 de susceptibilidad al cancer de mama ligado al cromosoma 13. Expired - Lifetime ES2190466T5 (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US576559 1984-02-03
US57377995A 1995-12-18 1995-12-18
US573779 1995-12-18
US57535995A 1995-12-20 1995-12-20
US575359 1995-12-20
US57655995A 1995-12-21 1995-12-21
US58539196A 1996-01-11 1996-01-11
US585391 1996-01-11
US639501 1996-04-29

Publications (2)

Publication Number Publication Date
ES2190466T3 true ES2190466T3 (es) 2003-08-01
ES2190466T5 ES2190466T5 (es) 2007-02-16

Family

ID=27504907

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96309211T Expired - Lifetime ES2190466T5 (es) 1995-12-18 1996-12-17 Gen brca2 de susceptibilidad al cancer de mama ligado al cromosoma 13.

Country Status (3)

Country Link
US (1) US5837492A (es)
EP (2) EP1260520B1 (es)
ES (1) ES2190466T5 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090269814A1 (en) * 1998-05-22 2009-10-29 Murphy Patricia D Method of Analyzing a BRCA2 Gene in a Human Subject
US20060154272A1 (en) * 1997-08-15 2006-07-13 Murphy Patricia D Novel coding sequence haplotypes of the human BRCA2 gene
JP2004532640A (ja) * 2001-06-05 2004-10-28 オークランド ユニサーヴィスィズ リミテッド 肺機能および障害の評価のための方法および組成物
JP2007514403A (ja) * 2003-08-21 2007-06-07 キュー セラピューティクス インコーポレイティッド リソソーム蓄積症において欠損しているリソソームプロ酵素の持続的分泌のための遺伝子改変体細胞
KR20080011289A (ko) * 2005-05-10 2008-02-01 시너젠즈 바이오사이언스 리미티드 폐기능 및 폐질환을 평가하기 위한 성분 및 평가 방법
CA2608158A1 (en) * 2005-05-19 2006-11-23 Synergenz Bioscience Limited Methods and compositions for assessment of pulmonary function and disorders
WO2006123955A2 (en) * 2005-05-19 2006-11-23 Synergenz Bioscience Limited Methods for the assesssment of risk of developing lung cancer using analysis of genetic polymorphisms
WO2006123943A1 (en) * 2005-05-20 2006-11-23 Synergenz Bioscience Limited Methods of analysis of polymorphisms and uses thereof
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
CN103424541B (zh) 2006-05-18 2018-01-30 分子压型学会股份有限公司 确定针对病状的个性化医疗介入的系统和方法
US20080085243A1 (en) * 2006-10-05 2008-04-10 Sigma-Aldrich Company Molecular markers for determining taxane responsiveness
US20100129358A1 (en) 2006-12-22 2010-05-27 University Of Utah Research Foundation Method of detecting ocular diseases and pathologic conditions and treatment of same
WO2010045318A2 (en) * 2008-10-14 2010-04-22 Caris Mpi, Inc. Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
WO2010056337A2 (en) 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
EP2542696B1 (en) 2010-03-01 2016-09-28 Caris Life Sciences Switzerland Holdings GmbH Biomarkers for theranostics
JP2013526852A (ja) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
JP6117194B2 (ja) 2011-06-17 2017-04-19 ミリアド・ジェネティックス・インコーポレイテッド アレル不均衡を評価するための方法および材料
US20130018700A1 (en) * 2011-07-14 2013-01-17 International Business Machines Corporation Optimizing product portfolios under customer choice
BR112014008862A2 (pt) 2011-10-14 2018-08-07 Genentech Inc anticorpo isolado que se liga à htra1, ácido nucleico isolado, célula hospedeira, imunoconjugado, formulação farmacêutica, métodos e usos
BR112014015152A2 (pt) 2011-12-21 2017-07-04 Myriad Genetics Inc métodos e materiais para a avaliação da perda de heterozigosidade
WO2013182645A1 (en) 2012-06-07 2013-12-12 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
US20140222512A1 (en) * 2013-02-01 2014-08-07 Goodsnitch, Inc. Receiving, tracking and analyzing business intelligence data
US20140343982A1 (en) * 2013-05-14 2014-11-20 Landmark Graphics Corporation Methods and systems related to workflow mentoring
WO2015073922A2 (en) 2013-11-15 2015-05-21 Northwestern University Inhibition of oxidative stress in atrial fibrillation
WO2015086473A1 (en) 2013-12-09 2015-06-18 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
JP6707028B2 (ja) 2013-12-09 2020-06-10 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 心筋細胞新生におけるｈｉｐｐｏ及びジストロフィン複合体シグナル伝達
US10133996B2 (en) * 2014-04-22 2018-11-20 International Business Machines Corporation Object lifecycle analysis tool
CN104111339B (zh) * 2014-06-26 2015-11-25 武汉市畜牧兽医科学研究所 基于BRCA2蛋白、mRNA诊断奶牛是否妊娠的方法及用途
CA2958801A1 (en) 2014-08-15 2016-02-18 Myriad Genetics, Inc. Methods and materials for assessing homologous recombination deficiency
EP3259346B1 (en) 2015-02-20 2024-08-07 Baylor College of Medicine P63 inactivation for the treatment of heart failure
CN104962613B (zh) * 2015-06-02 2019-12-03 南京医科大学 一种用于乳腺癌辅助诊断的突变基因及其应用
MY196448A (en) 2015-10-30 2023-04-12 Genentech Inc Anti-Htra1 Antibodies and Methods of use Thereof
USRE50319E1 (en) 2017-10-16 2025-03-04 Dana-Farber Cancer Institute, Inc. Compounds and methods for treating cancer
WO2019221991A1 (en) 2018-05-14 2019-11-21 Regents Of The University Of Minnesota Manipulating arid5b expression in immune cells to promote metabolism, survival, and function
RU2723585C2 (ru) * 2018-12-03 2020-06-16 федеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный университет" (ФГБОУ ВО "ВГУ") Способ диагностики предрасположенности к раку молочной железы в русской популяции на основе ПЦР-ПДРФ
CN110950958B (zh) * 2019-11-08 2022-07-22 江苏大学 一种抗brca2单克隆抗体及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
CA1188246A (en) 1981-08-31 1985-06-04 Jerry L. Gregory Immobilized microbe recycle apparatus
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4868105A (en) 1985-12-11 1989-09-19 Chiron Corporation Solution phase nucleic acid sandwich assay
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
IL103059A0 (en) 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
WO1995019369A1 (en) * 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer
DE69631540T2 (de) 1995-11-23 2005-01-27 Cancer Research Technology Ltd. Materialien und methoden mit bezug zur identifizierung und sequenzierung des krebs-suszeptilitaetsgens brca2 und dessen anwendungen

Also Published As

Publication number Publication date
EP2338913A1 (en) 2011-06-29
EP1260520A3 (en) 2002-12-04
US5837492A (en) 1998-11-17
EP1260520A2 (en) 2002-11-27
ES2190466T5 (es) 2007-02-16
EP1260520B1 (en) 2014-09-10

Similar Documents

Publication Publication Date Title
ES2190466T3 (es) Gen brca2 de susceptibilidad al cancer de mama ligado al cromosoma 13.
ES2164136T3 (es) Gen de susceptibilidad al cancer de mama y de ovarios asociado a 17q.
ATE230759T1 (de) Chromosom 13 verbundene brustkrebsempfindlichkeitsgen brca2
MX9701075A (es) Mutaciones en vivo y polimorfismos en el gen de susceptibilidad al cancer de pecho y ovario enlazado con 17q.
WO2003104275A3 (en) GENES AND POLYPEPTIDES RELATED TO COLON CANCER IN MAN
CY1105212T1 (el) Αντισωματα αντι-april και κυτταρα υβριδωματος
DE69432629D1 (de) Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
DE69717664D1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
CY1111863T1 (el) Αντισωματα εναντιον υποδοχεα θανατου 4 (dr4) και χρησεις αυτων
ATE315231T1 (de) Verfahren zur feststellung der anwesenheit mutierten brca proteins
Knudson et al. Distinct immunopeptide maps of the sarcoplasmic reticulum Ca2+ release channel in malignant hyperthermia.
DK0870036T3 (da) Syntetisk pattedyrs-alfa-N-acetylglucosaminidase og genetiske sekvenser kodende derfor
MX9701074A (es) Gen de susceptibilidad al cancer de pecho y ovario enlazado con 17q.
Ishii et al. Neurite outgrowth promoting function of α2-macroglobulin in central nervous system
Kobayashi et al. Characterization of hippocalcin: A hippocampus specific calcium-binding protein of recoverin family
Chiu et al. No association between an intronic presenilin-1 gene polymorphism and schizophrenia in a Chinese population
DE69934107D1 (de) Isolierte sh3 gene, die mit myeloproliferativen erkrankungen und leukämie verbunden sind, und deren verwendungen
EP1401505A4 (en) POPULATION OF HOXB8 MUTANTS AND USE IN IDENTIFICATION TO TREAT REPETITIVE BEHAVIOR